Project Grant R44CA306533
Award Date 9/10/25
Completion Date 8/31/26
Dollars Obligated $400K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Norwood, MA 02062, USA
Similar Awards
- This $1,022,522 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research federal grant program (CFDA 93.395) to Isoprene Pharmaceuticals Inc. The project aims to develop VNPP433-3beta (3B) as a novel therapeutic for all stages of prostate cancer. The key products and services include: The 3B compound, along with backup compounds 3B.HCl (VNPP548) and 3B.2HCl (VNPP595), are being evaluated as molecular glue degraders that simultaneously target the...
- The National Cancer Institute (NCI) awarded a $306,871 Project Grant to Vivere Oncotherapies, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to advance the development of their OV-151 oncolytic virotherapy product for the treatment of colorectal cancer. The project aims to: 1) characterize the delivery properties of the OV-151 clinical vector to tumors, 2) optimize the therapeutic cargo delivered by the vector, and 3) develop an inducible promoter to enhance...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,233,778 Project Grant to Matrisome Bio, Inc. to develop an extracellular matrix-targeted theranostic radiopharmaceutical for treating metastatic lung cancer. The funding will support research and development efforts to create molecularly targeted drugs using nanobodies that specifically bind to disease-associated extracellular matrix proteins in lung tumors and metastases. This novel approach aims to...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports the development of a novel, targeted small molecule inhibitor called TRE-515 by Trethera Corp, a clinical-stage biopharmaceutical company based in California. The $1,150,000 award will fund preclinical studies to evaluate TRE-515, which targets the deoxycytidine kinase (DCK) enzyme, as a potential combination therapy to prevent the DCK-mediated resistance mechanism in...
- The National Cancer Institute awarded a $1,634,811 Project Grant to Natsar Pharmaceuticals, Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding supports the drug development of RK-33, a small molecule inhibitor of the DDX3 RNA helicase, for the treatment of triple-negative breast cancers (TNBCs). TNBCs constitute 10-25% of all breast cancers and primarily affect younger women and African-American women, with limited treatment options. Preclinical studies...
- The National Cancer Institute, under the Cancer Treatment Research federal grant program (CFDA 93.395), awarded a $400,000 project grant to Nuago Therapeutics Inc. on June 9, 2025. The grant supports the development of a short RNA therapeutic to treat ovarian cancer. This research aims to develop a novel, targeted cancer therapy that can potentially overcome limitations of existing cancer treatments. The award has a projected completion date of May 31, 2026 and will be conducted at the company's...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- This $306,265 federal Project Grant, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on September 16, 2025, will fund the preclinical development of VAX024 - a novel, second-generation recombinant bacterial minicell-based targeted oncolytic in situ immunization (ISI) agent. VAX024 is designed to overcome limitations of current oncolytic viral therapies by leveraging the grantee's proprietary delivery technology to generate a sterile, user-friendly oncolytic...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $353,009 to Paramita Therapeutics Inc. to develop "Novel Multivalent PSMA-Targeted Taxane-Conjugates for Bone Metastases in Prostate Cancer." The project aims to synthesize and evaluate PSMA-targeted drug conjugates containing multiple copies of the taxane chemotherapies docetaxel or paclitaxel. The goal is to improve water solubility and selective targeting of prostate cancer...
- The U.S. National Cancer Institute awarded a Project Grant in the amount of $1,056,000.00 to the Sloan-Kettering Institute for Cancer Research, a leading cancer research organization located in New York. The grant, awarded under the federal Cancer Treatment Research program (CFDA 93.395), supports research focused on overcoming resistance to targeted therapies in breast cancer. The key objectives of the research project include elucidating the mechanisms underlying breast cancer plasticity and...